Alnylam RNAi Therapies

Select below to explore educational, scientific, and clinical resources related to the therapeutic areas in which Alnylam therapies are used. Information on investigational products or unlicensed indications is not included on this website.

UK healthcare professionals seeking further details may contact Alnylam Medical Information, where enquiries will be handled in accordance with UK Medical Information requirements. All material in this section is provided for scientific and educational purposes only.

Our RNAi Therapies

Access AMVUTTRA® (vutrisiran) Therapy Page

Click to Access AMVUTTRA® (vutrisiran) Therapy Page

AMVUTTRA® (vutrisiran)

Explore clinical and educational resources related to the use of vutrisiran in adult patients with hereditary transthyretin amyloidosis with stage 1 or stage 2 polyneuropathy (hATTR-PN) or wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

Access Prescribing Information

Transthyretin Amyloidosis (ATTR)

Access Vutrisiran Resources

Access ONPATTRO® (patisiran) Therapy Page

Click to Access ONPATTRO® (patrisiran) Therapy Page

ONPATTRO® (patisiran)

Explore clinical and educational resources related to the use of patisiran in adult patients hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with stage 1 or stage 2 polyneuropathy.

Access Prescribing Information

Transthyretin Amyloidosis (ATTR)

Access Patisiran Resources

Access GIVLAARI® (givosiran) Therapy Page

Click to Access GIVLAARI® (givosiran) Therapy Page

GIVLAARI® (givosiran)

Explore clinical and educational resources related to the use of givosiran in adult patients and adolescents aged 12 years and older with acute hepatic porphyria (AHP).

Access Prescribing Information

Acute Hepatic Porphyria (AHP)

Access Givosiran Resources